 Genetic Technologies Limited ASX: GTG; Nasdaq: GENE, Company is pleased to announce the full commissioning of its Australian Laboratory for the provisioning of its generation 3 breast cancer test with sales to commence in Q1, 2020. Genetype for Breast Cancer is the world first Genomic test to accurately predict risk of disease by combining the information contained in your DNA with family history and mammography data to create a powerful new tool in the battle with breast cancer. Unlike BRCA gene testing which is used to detect the 1 in 400 women who carry this cancer associated genetic mutation, Genetype for Breast Cancer is relevant for the better management of 95 of all Breast cancers which are referred to as sporadic or non-familial and is ideally suited to be the first line test in a preventative medical genomic based health system. 